AI uncovers potential cancer drivers hidden in ‘junk’ regions of DNA

FHS
July 3, 2024
3:28 am

Using artificial intelligence, Garvan Institute researchers have found potential cancer drivers hidden in so-called ‘junk’ regions of DNA, opening up possibilities for a new approach to diagnosis and treatment.

Boehringer Ingelheim unveils mid-stage win for glucagon/GLP-1 candidate for MASH, kindling PhIII plans

Boehringer Ingelheim said on Monday that its “double G” metabolic dysfunction-associated steatohepatitis (MASH) drug delivered positive topline results in a Phase II trial. The company

February 27, 2024

Citryll secures Series B funding for CIT-013

Phase IIa trials are set to focus on both rheumatoid arthritis and hidradenitis suppurativa, aiming to establish the antibody’s dual mechanism of action. Credit: CrizzyStudio/Shutterstock.

December 9, 2024

Attacks at US medical centers show why health care is one of the nation’s most violent fields

Word spread through an Oregon hospital last month that a visitor was causing trouble in the maternity ward, and nurses were warned the man might

August 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.